Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia

被引:4
作者
Korac, Petra [1 ]
Ajdukovic, Radmila [2 ]
Paro, Mirjana Mariana Kardum [3 ]
Jaksic, Branimir [4 ]
Dominis, Mara [1 ]
机构
[1] Univ Zagreb, Univ Hosp Merkur, Dept Pathol & Cytol, Zagreb 10000, Croatia
[2] Univ Zagreb, Dubrava Univ Hosp, Dept Med, Zagreb, Croatia
[3] Univ Zagreb, Univ Hosp Merkur, Inst Clin Chem, Zagreb 10000, Croatia
[4] Univ Zagreb, Univ Hosp Merkur, Dept Med, Zagreb 10000, Croatia
关键词
CLL; ZAP-70; CD45RO; Immunohistochemistry; Double immunofluorescence; Prognosis; VARIABLE-REGION MUTATIONS; CD38; EXPRESSION; GENE MUTATION; PROGNOSTIC-FACTOR; DISEASE; QUANTIFICATION; DIAGNOSIS; SURVIVAL;
D O I
10.1007/s10735-009-9213-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
This paper shows a protocol for the detection of ZAP-70 expression in B-CLL (B cell chronic lymphocytic leukemia) tumor cells by common immunohistochemical methods. The study was conducted on bone marrow trephine biopsies from 62 B-CLL patients at the time of diagnosis. Immunohistochemical reactions based on peroxidase and alkaline phosphatase reactions were used, as well as double immunofluorescent labeling for ZAP-70 detection as an indirect marker of mutated and unmutated CLL. Clinical relevance of the ZAP-70 expression detection method was assessed using chi (2) test between ZAP-70 positivity data and other known prognostic factors, i.e., clinical and cytogenetics data. ZAP-70 was detected in 13 out of 62 patients. Statistically significant results were obtained for ZAP-70 positive cases and known indicators of worse prognosis. Immunohistochemical analysis supported by double immunfluorescent labeling, as shown here, is an easy and reliable technique for the detection of ZAP-70 expression in B-CLL tumor cells applicable in every hematopathology laboratory.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 29 条
[1]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[2]  
2-V
[3]   ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia [J].
Castro, JE ;
Prada, CE ;
Loria, O ;
Kamal, A ;
Chen, LG ;
Burrows, FJ ;
Kipps, TJ .
BLOOD, 2005, 106 (07) :2506-2512
[4]   ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia [J].
Catherwood, MA ;
Matthews, C ;
Niblock, R ;
Dobbin, E ;
Morris, TCM ;
Alexander, HD .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (04) :294-298
[5]   Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia [J].
Chen, LG ;
Widhopf, G ;
Huynh, L ;
Rassenti, L ;
Rai, KR ;
Weiss, A ;
Kipps, TJ .
BLOOD, 2002, 100 (13) :4609-4614
[6]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[7]   CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia [J].
Chevallier, P ;
Penther, D ;
Avet-Loiseau, H ;
Robillard, N ;
Ifrah, N ;
Mahé, B ;
Hamidou, M ;
Maisonneuve, H ;
Moreau, P ;
Jardel, H ;
Harousseau, JL ;
Bataille, R ;
Garand, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) :142-150
[8]   Mechanisms of disease: Chronic lymphocytic leukemia [J].
Chiorazzi, N ;
Rai, KR ;
Ferrarini, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :804-815
[9]   ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].
Crespo, M ;
Bosch, F ;
Villamor, N ;
Bellosillo, B ;
Colomer, D ;
Rozman, M ;
Marcé, S ;
López-Guillermo, A ;
Campo, E ;
Montserrat, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775
[10]   CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia [J].
D'Arena, G ;
Musto, P ;
Cascavilla, N ;
Dell'Olio, M ;
Di Renzo, N ;
Perla, G ;
Savino, L ;
Carotenuto, M .
LEUKEMIA & LYMPHOMA, 2001, 42 (1-2) :109-114